[New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated]

Justine Bonnemort; Audrey Bellesoeur

doi:10.1016/j.bulcan.2021.04.004

[New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated]

Bull Cancer. 2021 Jul-Aug;108(7-8):673-675. doi: 10.1016/j.bulcan.2021.04.004. Epub 2021 Jun 23.

[Article in French]

Authors

Justine Bonnemort¹, Audrey Bellesoeur²

Affiliations

¹ Centre hospitalo-universitaire de Poitiers, département d'oncologie médicale, 86021 Poitiers, France. Electronic address: justine.bonnemort@hotmail.fr.
² Institut Curie, département d'oncologie médicale, 75005 Paris, France; Institut Curie, département de radio-pharmacologie, 92210 Saint-Cloud, France.

PMID: 34172272
DOI: 10.1016/j.bulcan.2021.04.004

No abstract available

Keywords: Brain metastases; Cancer du sein HER2 +; Cancer du sein métastatique; Capecitabine; HER2 positive breast cancer; Metastatic breast cancer; Métastases cérébrales; Trastuzumab; Tucatinib.

Publication types

News

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / chemistry*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Capecitabine / administration & dosage
Capecitabine / therapeutic use
Drug Approval*
Europe
Female
Humans
Oxazoles / administration & dosage
Oxazoles / therapeutic use
Pyridines / administration & dosage
Pyridines / therapeutic use
Quinazolines / administration & dosage
Quinazolines / therapeutic use
Receptor, ErbB-2* / antagonists & inhibitors
Trastuzumab / administration & dosage
Trastuzumab / therapeutic use

Substances

Oxazoles
Pyridines
Quinazolines
tucatinib
Capecitabine
Receptor, ErbB-2
Trastuzumab